Market Spotlight: Acne

This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.recasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2016, there were approximately 615 million prevalent cases of acne worldwide, and forecasts that number to increase to 673 million prevalent cases by 2025.

Approved drugs in the acne space target retinoic acid receptor, bacterial ribosome, bacterial protein synthesis, dihydropteroate synthetase, steroid 5a-reductase, estrogen receptor alpha, estrogen receptor beta, folate receptor, mineralocorticoid receptor, and progesterone receptor. These are commonly administered via the oral and topical routes.

The majority of industry-sponsored drugs in active clinical development for acne are in Phase II.

Therapies in mid-to-late-stage development for acne focus on a variety of targets. The majority of the drugs in mid-to-late-stage development for acne are administered via the topical route, with the remainder being oral, subcutaneous and intravenous.

High impact upcoming events for drugs in the acne space include topline Phase II and Phase III trial results. There were 21 licensing and asset acquisition activities involving acne drugs during 2012–17, seven of which occurred in 2014. The $50m license agreement between Actavis (now Allergan) and Mayne Pharma, pursuant to which Actavis will divest the US rights to Doryx brand acne treatment and related assets to Mayne, was the largest deal during the 201217 period.

Yaz’s sales ranked highest among drugs available for acne during 2012–16. The clinical trials distribution across Phase I–IV indicates that the majority of trials for acne have been in late phases of development, with 55% of trials in Phase III–IV, and 45% in Phase I–III.

The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

GlaxoSmithKline has the highest number of completed clinical trials for acne

Exclusive Sample Report @ https://www.reportsworldwide.com/enquiry?report_id=42607

Major Table of Contents

1 KEY TAKEAWAYS

2 DISEASE BACKGROUND

3 TREATMENT
4 Topical therapy
5 Systemic therapy
6 Physical treatments

7 EPIDEMIOLOGY

8 MARKETED DRUGS
9 Approvals by country

10 PIPELINE DRUGS

11 KEY UPCOMING EVENTS

12 KEY REGULATORY EVENTS
13 Galderma Pioneers NDA Path Into OTC Acne Treatment Market
14 Indian Start-up Vyome Wins Milestone FDA Nod For Acne Studies

15 LICENSING AND ASSET ACQUISITION DEALS
16 Sato licenses Japanese rights to Novan's acne candidate SB204

17 PARENT PATENTS

18 REVENUE OPPORTUNITY

19 CLINICAL TRIAL LANDSCAPE
20 Sponsors by status
21 Sponsors by phase
22 Acne Pipeline Yields Three Disappointments, One Win So Far In 2017
23 Xenon Down On Novel Acne Treatment Failure

24 BIBLIOGRAPHY
25 Prescription information:

26 APPENDIX

LIST OF FIGURES

11 Figure 1: Trends in prevalent cases of acne, 2016–25
22 Figure 2: Pipeline drugs for acne in the US
22 Figure 3: Pipeline drugs for acne, by country
23 Figure 4: Pipeline drugs for acne, by drug type
23 Figure 5: Pipeline drugs for acne, by classifications
29 Figure 6: Key upcoming events in acne
31 Figure 7: Licensing and asset acquisition deals in acne
32 Figure 8: Parent patents in acne
35 Figure 9: Clinical trials in acne
35 Figure 10: Top 10 drugs for clinical trials in acne
36 Figure 11: Top 10 companies for clinical trials in acne
36 Figure 12: Trial locations in acne
37 Figure 13: Acne trials sponsors, by status
38 Figure 14: Acne trials sponsors, by phase

LIST OF TABLES

10 Table 1: Prevalent cases of acne, 2016–25
13 Table 2: Marketed drugs for acne
18 Table 3: Approvals by country for acne
24 Table 4: Pipeline drugs for acne in the US
33 Table 5: Historical global sales, by drug ($m), 2012–16
34 Table 6: Forecasted global sales, by drug ($m), 2017–22

Ask to Expertise @ https://www.reportsworldwide.com/enquiry?report_id=42607

About US:

Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of market research reports provides in depth coverage of 12 top industry verticals worldwide. We help you meet your market intelligence needs by mapping it with our database of market research reports including.

Contact Us:

Email: sales@reportsworldwide.com

Phone: +1 (617) 398-1947